Etoperidone is an atypical antidepressant introduced in Europe in 1977. It is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a... Etoperidone was developed by Angelini Francesco ACRAF.
- Mechanism
- Curator reviewed · 1 reference
The activity of etoperidone is made mainly by its major metabolite 1-(3'-chlorophenyl)piperazine (mCPP). mCPP binds with different affinity to most of the serotonergic receptors and adrenergic receptors. This metabolite is an agonist of 5-HT2c and an antagonist of 5-HT2a. Part of etoperidone structure contibutes to the activity in the α-adrenergic receptors.
- Primary indication
- Etoperidone has been studied for the treatment of depression, tremors in Parkinson, extrapyramidal symptoms and male impotence.Curator reviewed
- Formula / weight
- C19H28ClN5O · 377.92 g/mol (avg)
- Code names
- ST-1191
Resolves to
IZBNNCFOBMGTQX-UHFFFAOYSA-NSMILESCCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CCWhat you can answer from here — as of September 12, 2026
Which drugs share a target with Etoperidone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account